159 related articles for article (PubMed ID: 29053717)
1. GPR40 partial agonists and AgoPAMs: Differentiating effects on glucose and hormonal secretions in the rodent.
Pachanski MJ; Kirkland ME; Kosinski DT; Mane J; Cheewatrakoolpong B; Xue J; Szeto D; Forrest G; Miller C; Bunzel M; Plummer CW; Chobanian HR; Miller MW; Souza S; Thomas-Fowlkes BS; Ogawa AM; Weinglass AB; Di Salvo J; Li X; Feng Y; Tatosian DA; Howard AD; Colletti SL; Trujillo ME
PLoS One; 2017; 12(10):e0186033. PubMed ID: 29053717
[TBL] [Abstract][Full Text] [Related]
2. Potentiation of insulin secretion and improvement of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist DS-1558 with glucagon-like peptide-1 receptor agonists.
Nakashima R; Yano T; Ogawa J; Tanaka N; Toda N; Yoshida M; Takano R; Inoue M; Honda T; Kume S; Matsumoto K
Eur J Pharmacol; 2014 Aug; 737():194-201. PubMed ID: 24858371
[TBL] [Abstract][Full Text] [Related]
3. GPR40 reduces food intake and body weight through GLP-1.
Gorski JN; Pachanski MJ; Mane J; Plummer CW; Souza S; Thomas-Fowlkes BS; Ogawa AM; Weinglass AB; Di Salvo J; Cheewatrakoolpong B; Howard AD; Colletti SL; Trujillo ME
Am J Physiol Endocrinol Metab; 2017 Jul; 313(1):E37-E47. PubMed ID: 28292762
[TBL] [Abstract][Full Text] [Related]
4. Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice.
Tan CP; Feng Y; Zhou YP; Eiermann GJ; Petrov A; Zhou C; Lin S; Salituro G; Meinke P; Mosley R; Akiyama TE; Einstein M; Kumar S; Berger JP; Mills SG; Thornberry NA; Yang L; Howard AD
Diabetes; 2008 Aug; 57(8):2211-9. PubMed ID: 18477808
[TBL] [Abstract][Full Text] [Related]
5. Novel GPR40 agonist AS2575959 exhibits glucose metabolism improvement and synergistic effect with sitagliptin on insulin and incretin secretion.
Tanaka H; Yoshida S; Minoura H; Negoro K; Shimaya A; Shimokawa T; Shibasaki M
Life Sci; 2014 Jan; 94(2):115-21. PubMed ID: 24269216
[TBL] [Abstract][Full Text] [Related]
6. GPR40-Mediated G
Rives ML; Rady B; Swanson N; Zhao S; Qi J; Arnoult E; Bakaj I; Mancini A; Breton B; Lee SP; Player MR; Pocai A
Mol Pharmacol; 2018 Jun; 93(6):581-591. PubMed ID: 29572336
[TBL] [Abstract][Full Text] [Related]
7. Chronic treatment with novel GPR40 agonists improve whole-body glucose metabolism based on the glucose-dependent insulin secretion.
Tanaka H; Yoshida S; Oshima H; Minoura H; Negoro K; Yamazaki T; Sakuda S; Iwasaki F; Matsui T; Shibasaki M
J Pharmacol Exp Ther; 2013 Sep; 346(3):443-52. PubMed ID: 23853170
[TBL] [Abstract][Full Text] [Related]
8. SCO-267, a GPR40 Full Agonist, Improves Glycemic and Body Weight Control in Rat Models of Diabetes and Obesity.
Ueno H; Ito R; Abe SI; Ookawara M; Miyashita H; Ogino H; Miyamoto Y; Yoshihara T; Kobayashi A; Tsujihata Y; Takeuchi K; Watanabe M; Yamada Y; Maekawa T; Nishigaki N; Moritoh Y
J Pharmacol Exp Ther; 2019 Aug; 370(2):172-181. PubMed ID: 31182471
[TBL] [Abstract][Full Text] [Related]
9. GPR40 full agonism exerts feeding suppression and weight loss through afferent vagal nerve.
Ueno H; Ito R; Abe SI; Ogino H; Maruyama M; Miyashita H; Miyamoto Y; Moritoh Y; Tsujihata Y; Takeuchi K; Nishigaki N
PLoS One; 2019; 14(9):e0222653. PubMed ID: 31525244
[TBL] [Abstract][Full Text] [Related]
10. GPR40 protein levels are crucial to the regulation of stimulated hormone secretion in pancreatic islets. Lessons from spontaneous obesity-prone and non-obese type 2 diabetes in rats.
Meidute Abaraviciene S; Muhammed SJ; Amisten S; Lundquist I; Salehi A
Mol Cell Endocrinol; 2013 Dec; 381(1-2):150-9. PubMed ID: 23911664
[TBL] [Abstract][Full Text] [Related]
11. GPR40 partial agonist MK-2305 lower fasting glucose in the Goto Kakizaki rat via suppression of endogenous glucose production.
Miller C; Pachanski MJ; Kirkland ME; Kosinski DT; Mane J; Bunzel M; Cao J; Souza S; Thomas-Fowlkes B; Di Salvo J; Weinglass AB; Li X; Myers RW; Knagge K; Carrington PE; Hagmann WK; Trujillo ME
PLoS One; 2017; 12(5):e0176182. PubMed ID: 28542610
[TBL] [Abstract][Full Text] [Related]
12. Design and Synthesis of Novel, Selective GPR40 AgoPAMs.
Plummer CW; Clements MJ; Chen H; Rajagopalan M; Josien H; Hagmann WK; Miller M; Trujillo ME; Kirkland M; Kosinski D; Mane J; Pachanski M; Cheewatrakoolpong B; Nolting AF; Orr R; Christensen M; Campeau LC; Wright MJ; Bugianesi R; Souza S; Zhang X; Di Salvo J; Weinglass AB; Tschirret-Guth R; Nargund R; Howard AD; Colletti SL
ACS Med Chem Lett; 2017 Feb; 8(2):221-226. PubMed ID: 28197316
[TBL] [Abstract][Full Text] [Related]
13. Discovery of Potent and Orally Bioavailable GPR40 Full Agonists Bearing Thiophen-2-ylpropanoic Acid Scaffold.
Li H; Huang Q; Chen C; Xu B; Wang HY; Long YQ
J Med Chem; 2017 Apr; 60(7):2697-2717. PubMed ID: 28277660
[TBL] [Abstract][Full Text] [Related]
14. Acute administration of GPR40 receptor agonist potentiates glucose-stimulated insulin secretion in vivo in the rat.
Doshi LS; Brahma MK; Sayyed SG; Dixit AV; Chandak PG; Pamidiboina V; Motiwala HF; Sharma SD; Nemmani KV
Metabolism; 2009 Mar; 58(3):333-43. PubMed ID: 19217448
[TBL] [Abstract][Full Text] [Related]
15. AMG 837: a novel GPR40/FFA1 agonist that enhances insulin secretion and lowers glucose levels in rodents.
Lin DC; Zhang J; Zhuang R; Li F; Nguyen K; Chen M; Tran T; Lopez E; Lu JY; Li XN; Tang L; Tonn GR; Swaminath G; Reagan JD; Chen JL; Tian H; Lin YJ; Houze JB; Luo J
PLoS One; 2011; 6(11):e27270. PubMed ID: 22087278
[TBL] [Abstract][Full Text] [Related]
16. Optimization of physicochemical properties of pyrrolidine GPR40 AgoPAMs results in a differentiated profile with improved pharmacokinetics and reduced off-target activities.
Jurica EA; Wu X; Williams KN; Haque LE; Rampulla RA; Mathur A; Zhou M; Cao G; Cai H; Wang T; Liu H; Xu C; Kunselman LK; Antrilli TM; Hicks MB; Sun Q; Dierks EA; Apedo A; Moore DB; Foster KA; Cvijic ME; Panemangalore R; Khandelwal P; Wilkes JJ; Zinker BA; Robertson DG; Janovitz EB; Galella M; Li YX; Li J; Ramar T; Jalagam PR; Jayaram R; Whaley JM; Barrish JC; Robl JA; Ewing WR; Ellsworth BA
Bioorg Med Chem; 2023 May; 85():117273. PubMed ID: 37030194
[TBL] [Abstract][Full Text] [Related]
17. A potent class of GPR40 full agonists engages the enteroinsular axis to promote glucose control in rodents.
Luo J; Swaminath G; Brown SP; Zhang J; Guo Q; Chen M; Nguyen K; Tran T; Miao L; Dransfield PJ; Vimolratana M; Houze JB; Wong S; Toteva M; Shan B; Li F; Zhuang R; Lin DC
PLoS One; 2012; 7(10):e46300. PubMed ID: 23056280
[TBL] [Abstract][Full Text] [Related]
18. The acute glucose lowering effect of specific GPR120 activation in mice is mainly driven by glucagon-like peptide 1.
Sundström L; Myhre S; Sundqvist M; Ahnmark A; McCoull W; Raubo P; Groombridge SD; Polla M; Nyström AC; Kristensson L; Någård M; Winzell MS
PLoS One; 2017; 12(12):e0189060. PubMed ID: 29206860
[TBL] [Abstract][Full Text] [Related]
19. Evaluating insulin secretagogues in a humanized mouse model with functional human islets.
Luo J; Nguyen K; Chen M; Tran T; Hao J; Tian B; Rulifson IC; Zhang Y; Tian L; Zhang Y; Lopez E; Lin DC; Wang Y; Ma Z; Houze J; Guo Z
Metabolism; 2013 Jan; 62(1):90-9. PubMed ID: 22982177
[TBL] [Abstract][Full Text] [Related]
20. Combined Deletion of Free Fatty-Acid Receptors 1 and 4 Minimally Impacts Glucose Homeostasis in Mice.
Croze ML; Guillaume A; Ethier M; Fergusson G; Tremblay C; Campbell SA; Maachi H; Ghislain J; Poitout V
Endocrinology; 2021 Mar; 162(3):. PubMed ID: 33543237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
